Your account is not claimed yet. You can sign up with ORCID to claim your account.

Carlos F Lagos

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 4

Top Topics

Circulating Tumor

Molecular Dynamics Simulations

Neoadjuvant Chemotherapy

Top Venues

Pharmaceuticals (Basel, Switzerland)

Nature communications

Molecules (Basel, Switzerland)

Journal of the Endocrine Society

Universidad San Sebastián

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universidad San Sebastián May 2o 2018

Chile

Profesor Asistente :: Facultad de Medicina y Ciencia

Publications

Loreto Arrieta-Rodríguez, Daniela Espinoza-Rosales, Gonzalo Vera, Young Hwa Cho, David Cabezas, David Vásquez-Velásquez, Jaime Mella-Raipán, Carlos F Lagos, Gonzalo Recabarren-Gajardo
Novel N-Arylsulfonylindoles Targeted as Ligands of the 5-HT6 Receptor. Insights on the Influence of C-5 Substitution on Ligand Affinity. Pharmaceuticals (Basel, Switzerland) 14 (6) (2021)
Bruno A Cisterna, Aníbal A Vargas, Carlos Puebla, Paola Fernández, Rosalba Escamilla, Carlos F Lagos, María F Matus, Cristian Vilos, Luis A Cea, Esteban Barnafi, Hugo Gaete, Daniel F Escobar, Christopher P Cardozo, Juan C Sáez
Active acetylcholine receptors prevent the atrophy of skeletal muscles and favor reinnervation. Nature communications 11 (1) (2020)
Federica Buonocore, Oliver Clifford-Mobley, Thomas F J King, Niccolò Striglioni, Elim Man, Jenifer P Suntharalingham, Ignacio Del Valle, Lin Lin, Carlos F Lagos, Gill Rumsby, Gerard S Conway, John C Achermann
Next-Generation Sequencing Reveals Novel Genetic Variants (SRY, DMRT1, NR5A1, DHH, DHX37) in Adults With 46,XY DSD. Journal of the Endocrine Society 3 (12) (2019)
Carlos F Lagos, Gerardine F Segovia, Nicolás Nuñez-Navarro, Mario A Faúndez, Flavia C Zacconi
Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches. Molecules (Basel, Switzerland) 22 (10) (2017)